Michael John Costanzo

4 Patents

• US125952462026

  Crystalline and Amorphous Forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2h-indazol-5-yl)pyrimidin-2-amine and Its Salts, and Preparation Methods and Therapeutic Uses Thereof

  BETA PHARMA, Inc.

  0 cites
• US123904642025

  Treatment of EGFR Mutant-related Cancers Using a Combination of EGFR and CDK4/6 Inhibitors

  BETA PHARMA, Inc.

  0 cites
• US122583652025

  Organophosphorus-substituted Compounds as C-met Inhibitors and Therapeutic Uses Thereof

  BETA PHARMA, Inc.

  0 cites
• US121877072025

  Pharmaceutical Formulations of N -(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and Salts Thereof

  BETA PHARMA, Inc.

  0 cites